AR046603A1 - Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc - Google Patents
Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el sncInfo
- Publication number
- AR046603A1 AR046603A1 ARP040103867A ARP040103867A AR046603A1 AR 046603 A1 AR046603 A1 AR 046603A1 AR P040103867 A ARP040103867 A AR P040103867A AR P040103867 A ARP040103867 A AR P040103867A AR 046603 A1 AR046603 A1 AR 046603A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- nitrogen
- sulfur
- alkyl
- oxygen
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 12
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 6
- 229910052760 oxygen Chemical group 0.000 abstract 6
- 239000001301 oxygen Chemical group 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 239000011593 sulfur Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 4
- 229920001774 Perfluoroether Polymers 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- -1 cyano, hydroxyl Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Se proporcionan compuestos o sales farmacéuticamente aceptables de los mismos: que son agonistas o agonistas parciales de los receptores del subtipo 2c de la serotonina cerebral. Los compuestos, y composiciones que contienen los compuestos, se pueden utilizar para tratar una variedad de trastornos del sistema nervioso central de tales como esquizofrenia. Reivindicación 1: Un compuesto de fórmula (1), o sales farmacéuticamente aceptables de los mismos; donde R y R' son, independientemente, hidrógeno, alquilo C1-6, cicloalquilo C3-6, o alquilcicloalquilo C4-12 que tienen de 3 a 6 carbonos en el anillo cicloalquilo; alternativamente R y R' se pueden tomar juntos con el nitrógeno al que están adheridos para formar un anillo C2-5, donde uno de los átomos de carbono del anillo está sustituido opcionalmente por nitrógeno, azufre u oxígeno; R1 y R2 son, cada uno, independientemente, hidrógeno, alquilo C1-6, cicloalquilo C3-6, o perfluoroalquilo C1-6; R3a y R3b son, independientemente, hidrógeno, halógeno, hidroxilo, alquilo C1-6, perfluoroalquilo C1-6, alcoxi C1-6, o perfluoroalcoxi C1-6; dos sustituyentes adyacentes seleccionados entre R4 y R5, o R5 y R6, o R6 y R7, junto con los átomos de carbono a los que están adheridos, forman una estructura cíclica seleccionada entre un cicloalquilo monocíclico C3-8, un cicloalquilo que forma un puente C5-10, un heterocicloalquilo de 3 a 8 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionadas independientemente entre nitrógeno, oxígeno, o azufre, arilo C5-10, o un heteroarilo de 5 a 10 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionadas independientemente entre nitrógeno, oxígeno, o azufre, donde la estructura monocíclica cicloalquilo o la estructura cíclica heterocicloalquilo pueden estar opcionalmente sustituidas en un único átomo de carbono con un cicloalquilo C3-5 o un heterocicloalquilo de 3 a 5 miembros que contienen 1 ó 2 heteroátomos cada uno seleccionados independientemente entre nitrógeno, oxígeno, o azufre, para formar un grupo espirocíclico; los restantes sustituyentes R4 a R7 son, independientemente, hidrógeno, halógeno, ciano, hidroxilo, carboxilo, alquilo C1-8, perfluoroalquilo C1-6, alcoxi C1- 6, perfluoroalcoxi C1-6, arilo C5-10, ariloxi C5-10, heteroarilo de 5 a 10 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionados independientemente entre nitrógeno, oxígeno o azufre, alquenilo C2-8, alcanoilo C2-6, alcanoiloxi C2-6, carboalcoxi C2-6, carboxamido, alcanamido C2-6, alcanosulfonamido C1-6, amino, monoalquilamino C1-6, dialquilamino C1-6 por una estructura alquilo, cicloalquilo C3-8, o heterocicloalquilo de 3 a 8 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionados independientemente entre nitrógeno, oxígeno o azufre; y n es 1, 2 ó 3; donde cualquier grupo cicloalquilo o heterocicloalquilo está saturado o parcialmente saturado, y cualquier grupo arilo, heteroarilo, cicloalquilo, o heterocicloalquilo puede estar opcionalmente sustituido con 1 a 5 sustituyentes seleccionados independientemente entre halógeno, hidroxilo, alquilo C1-6, perfluoroalquilo C1-6, alcoxi C1-6, o perfluoroalcoxi C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51426603P | 2003-10-24 | 2003-10-24 | |
| US10/970,103 US7728155B2 (en) | 2003-10-24 | 2004-10-21 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046603A1 true AR046603A1 (es) | 2005-12-14 |
Family
ID=34526975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103867A AR046603A1 (es) | 2003-10-24 | 2004-10-25 | Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7728155B2 (es) |
| EP (1) | EP1675842A1 (es) |
| JP (1) | JP2007509167A (es) |
| AR (1) | AR046603A1 (es) |
| AU (1) | AU2004284072A1 (es) |
| BR (1) | BRPI0415769A (es) |
| CA (1) | CA2541472A1 (es) |
| MX (1) | MXPA06004344A (es) |
| TW (1) | TW200522942A (es) |
| WO (1) | WO2005040146A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
| GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
| CA2603900A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| BRPI0610037A2 (pt) * | 2005-04-22 | 2010-05-25 | Wyeth Corp | derivados de dihidrobenzofurano e uso dos mesmos |
| GT200600159A (es) * | 2005-04-22 | 2007-03-14 | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| AU2006239922A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists |
| CA2605447A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
| TW200716584A (en) * | 2005-04-22 | 2007-05-01 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
| CN101203505A (zh) * | 2005-04-22 | 2008-06-18 | 惠氏公司 | 苯并二氢吡喃和苯并吡喃衍生物及其用途 |
| MX2007012882A (es) * | 2005-04-22 | 2007-12-10 | Wyeth Corp | Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion. |
| EP1871354A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Treatment of pain |
| US20060258712A1 (en) * | 2005-04-24 | 2006-11-16 | Wyeth | Methods for modulating bladder function |
| AR060090A1 (es) * | 2006-03-24 | 2008-05-21 | Wyeth Corp | Metodos para tratar trastornos cognitivos y otros afines |
| US8158617B2 (en) | 2006-05-16 | 2012-04-17 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND ITS USE |
| JP5526793B2 (ja) | 2009-03-18 | 2014-06-18 | Jnc株式会社 | 重合性液晶化合物、重合性液晶組成物およびその重合体 |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1200892A (en) | 1966-10-27 | 1970-08-05 | Ward Blenkinsop & Co Ltd | Production of 2-aminomethyl-2,3-dihydrobenzofurans |
| US3513239A (en) | 1967-03-15 | 1970-05-19 | Smithkline Corp | Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith |
| US3826835A (en) | 1971-01-08 | 1974-07-30 | Ciba Geigy Corp | 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics |
| JPS59186969A (ja) | 1983-04-08 | 1984-10-23 | Yoshitomi Pharmaceut Ind Ltd | ベンゾフラン−およびベンゾピランカルボキサミド誘導体 |
| US5008286A (en) * | 1985-11-22 | 1991-04-16 | Burroughs Wellcome Co. | Certain substituted naphthofurans with anti-tumor properties |
| FR2601950B1 (fr) | 1986-07-22 | 1988-11-10 | Cerm Cent Europ Rech Mauvernay | N,n-dimethyl-n'-benzoyl-n' ((2,3-dihydro) benzofuran-2-yl-methyl) 1,3-propanediamine, preparation et compositions pharmaceutiques les contenant |
| IT1239946B (it) | 1990-03-12 | 1993-11-27 | Biomedica Foscama Industria Chimicofarmaceutica | Procedimento per la sintesi degli acidi 5-acilossi e 5-alcossi-2,3-diidro-4,6,7-trimetil-2-(rs)-benzofuranacetici |
| WO1991017144A1 (fr) | 1990-05-02 | 1991-11-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose amide, utilisation pharmaceutique de ce compose et nouvelles pyrrolidinemethyl-amines 1-substituee |
| JPH05194406A (ja) | 1991-11-12 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 新規アミド化合物 |
| JP3153335B2 (ja) | 1992-06-05 | 2001-04-09 | 興和株式会社 | キノリン誘導体又はその塩 |
| FR2701479B1 (fr) | 1993-02-11 | 1995-05-12 | Pf Medicament | Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique. |
| JPH06316563A (ja) | 1993-05-06 | 1994-11-15 | Yoshitomi Pharmaceut Ind Ltd | アミド化合物 |
| JP2999669B2 (ja) | 1993-08-24 | 2000-01-17 | 株式会社三和化学研究所 | ベンゾ[b]フランカルボキサミド誘導体、その製法及び用途 |
| DE69524528T2 (de) | 1994-10-14 | 2002-08-01 | Merck Patent Gmbh | ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman |
| WO1996030367A1 (en) | 1995-03-27 | 1996-10-03 | Hisamitsu Pharmaceutical Co., Inc. | Piperidine derivatives |
| EP0846683B1 (en) | 1996-12-03 | 2001-09-19 | F. Hoffmann-La Roche Ag | 4-Hydroxy-piperidine derivatives |
| JP2000007671A (ja) | 1998-06-25 | 2000-01-11 | Asahi Chem Ind Co Ltd | 2,3−ジヒドロベンゾフラン誘導体 |
| JP2000080091A (ja) | 1998-06-26 | 2000-03-21 | Asahi Chem Ind Co Ltd | 2,3―ジヒドロベンゾフラン誘導体の製造方法 |
| US6255324B1 (en) | 1998-11-25 | 2001-07-03 | Ned D. Heindel | Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof |
| HK1042480A1 (zh) | 1999-06-15 | 2002-08-16 | Bristol-Myers Squibb Pharma Company | 取代的稠杂环γ-咔啉 |
| SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| US6872718B1 (en) | 1999-08-20 | 2005-03-29 | Takeda Chemical Industries, Ltd. | Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| WO2003022814A1 (en) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Indole derivatives |
| US7153852B2 (en) | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
| US6569894B1 (en) | 2001-10-04 | 2003-05-27 | Bristol-Myers Squibb Company | Arylalkylbenzofuran derivatives as melatonergic agents |
| EP1348708A1 (en) | 2002-02-28 | 2003-10-01 | Sanofi-Synthelabo | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
| US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
-
2004
- 2004-10-21 US US10/970,103 patent/US7728155B2/en not_active Expired - Fee Related
- 2004-10-22 CA CA002541472A patent/CA2541472A1/en not_active Abandoned
- 2004-10-22 WO PCT/US2004/035043 patent/WO2005040146A1/en not_active Ceased
- 2004-10-22 BR BRPI0415769-9A patent/BRPI0415769A/pt not_active IP Right Cessation
- 2004-10-22 AU AU2004284072A patent/AU2004284072A1/en not_active Withdrawn
- 2004-10-22 MX MXPA06004344A patent/MXPA06004344A/es active IP Right Grant
- 2004-10-22 JP JP2006536828A patent/JP2007509167A/ja not_active Withdrawn
- 2004-10-22 EP EP04817336A patent/EP1675842A1/en not_active Withdrawn
- 2004-10-22 TW TW093132108A patent/TW200522942A/zh unknown
- 2004-10-25 AR ARP040103867A patent/AR046603A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2541472A1 (en) | 2005-05-06 |
| JP2007509167A (ja) | 2007-04-12 |
| US20050124692A1 (en) | 2005-06-09 |
| WO2005040146A1 (en) | 2005-05-06 |
| TW200522942A (en) | 2005-07-16 |
| BRPI0415769A (pt) | 2006-12-26 |
| MXPA06004344A (es) | 2006-06-05 |
| EP1675842A1 (en) | 2006-07-05 |
| US7728155B2 (en) | 2010-06-01 |
| AU2004284072A1 (en) | 2005-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046603A1 (es) | Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc | |
| AR046309A1 (es) | Derivados de dihidrobenzofuranilo alcanamina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos del sistema nervioso central. | |
| AR050433A1 (es) | Derivados piperidilo de quinazolina e isoquinolina | |
| AR065718A1 (es) | Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos. | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| CO5570676A2 (es) | Nuevos compuestos de alquilo con efecto antagonico de la hcm y medicamentos que contienen estos compuestos | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| AR056320A1 (es) | Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos | |
| AR056879A1 (es) | Antagonistas del receptor 3 de la histamina | |
| ES2179490T3 (es) | Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5. | |
| AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| AR051090A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
| CR9959A (es) | Derivados de pirazol | |
| AR059686A1 (es) | Piperazinas terapeuticas | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR118082A1 (es) | Inhibidores de enzimas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |